M&A claims diligence
A quality-of-earnings review never touches the claims a supplement target makes in public. We rule every one against FDA, FTC and Health Canada rules and marketplace policy, and hand you a signed exhibit written for a deal room in five business days.
The engine behind this review has run 149,000+ phrase checks, and 75% of the top-selling listings it has ruled carry at least one finding serious enough to fail an FDA, FTC or marketplace standard.
Scope a target
The exhibit
Every public claim the target makes, ruled and rated by severity, with every fix written and sized by what it takes. A redacted sample report is public, and the diligence exhibit format is available before any engagement.
In scope for every target
A claims exhibit dated after closing is not diligence, it is an explanation. It is worth having because it exists before the price is agreed, the only window in which a finding can still move the price.
If a marketplace or regulator acts on the target’s copy after close, your side gets asked what was done to check it, and by whom. A dated exhibit signed by a named licensed reviewer answers that. A warranty from the seller does not.
Flat, whether the target comes back clean or badly exposed. Nobody here is paid more for a worse result, which is the first thing a seller’s counsel asks about whoever produced the exhibit.
What this exhibit does not do is promise that no platform or regulator ever acts on the target’s copy. Nobody can promise that. It records which claims were reviewed, against which published standards, on what date, and by whom. That is what a diligence file is for.
Why it’s a line item
A QoE looks at revenue. Legal diligence looks at contracts. The claims on the listing sit in neither.
An unsupported “clinically proven” on the hero SKU carries an FTC penalty of up to $53,088 per violation, the published ceiling rather than a forecast, and it transfers at closing.
Roughly 670 marketers are already on formal FTC penalty notice over health-claim substantiation.Trade press reported that from 31 March 2026 Amazon began requiring detail-page content to match the Supplement Facts panel, enforced automatically. Amazon has not published that policy, and its published Restricted Products rules already allow suppression without notice. Copy written three owners ago can take a target’s revenue off sale.
Amazon’s published supplement policy names prescription-equivalence claims, including GLP-1, as prohibited outright.Found in diligence, the findings are in front of both sides before the price is fixed. Found after closing, they sit with the buyer.
Plaintiffs read the same copy your buyers do, and quote it back as the exhibit.Both sides of the table
The same review, run by whoever gets there first.
A per-target report before the LOI firms up, or a portfolio sweep across existing holdings. Your dashboard shows the portfolio product by product, each ranked against every top-selling listing in its category with every fix counted by what it takes, for your IC to weigh against the price.
A clean claims file before the data room opens: the review a buy-side team would run, run first, with every finding rewritten compliant before the file goes out. A brand that passes also qualifies for the public directory of verified brands, a third-party reference an acquirer can check from the data room.
Brokers and bankers: we work referral terms, ask.
How it runs
Five days works because the sweep is machine-run, with a pharmacist-in-the-loop on every ruling.
NDA if needed. We work entirely from public copy with no seller cooperation, so the review can run pre-LOI without tipping the process.
The same system behind 149,000+ phrase checks across the top-selling set reads every target surface, and a licensed pharmacist signs every ruling that reaches the exhibit.
Or at hour 48 on rush: the signed report, your dashboard with the portfolio view product by product, and a working session with your deal team. A redacted sample report is available before any engagement.
Monitoring keeps the acquired portfolio under scan: monthly re-scans of every acquired surface, an alert within 48 hours of a new Critical finding, and a dated changelog of what changed and when.
Scope a review
Email audit@claimsverified.org with the subject “Diligence”, or use the request form and note “Diligence”. Same-day response.
Review of marketing language only, not product testing, formulation, facility compliance, financial or legal advice. Findings are our opinion under the published Claims Verified standards.